Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study

Basit Öğe Kaydı
dc.authoridDagdelen, Selcuk/0000-0002-0513-1750
dc.authoridDemirci, Ibrahim/0000-0003-0498-3115
dc.authoridsahin, mustafa/0000-0002-4718-0083
dc.authoridSonmez, Alper/0000-0002-9309-7715
dc.authoridSatman, Ilhan/0000-0001-8613-1797
dc.authoridcelik, osman/0000-0003-2131-2866
dc.authoridTASCI, ILKER/0000-0002-0936-2476
dc.authorwosidDagdelen, Selcuk/A-9432-2017
dc.authorwosidArga, Kazım Yalçın/HGB-8786-2022
dc.authorwosidDemirci, Ibrahim/AAR-3277-2020
dc.authorwosidsahin, mustafa/AAH-3394-2019
dc.authorwosidUnluturk, Ugur/A-1988-2016
dc.authorwosidUstun, Yaprak/KFQ-9767-2024
dc.authorwosidCelik, Osman/KLZ-6766-2024
dc.contributor.authorEmral, Rifat
dc.contributor.authorHaymana, Cem
dc.contributor.authorDemirci, Ibrahim
dc.contributor.authorTasci, Ilker
dc.contributor.authorSahin, Mustafa
dc.contributor.authorCakal, Erman
dc.contributor.authorAta, Naim
dc.date.accessioned2024-08-04T20:50:33Z
dc.date.available2024-08-04T20:50:33Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction To investigate the effect of preexisting treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) on COVID-19-related hospitalization and mortality in patients with type 2 diabetes mellitus (T2DM). Methods A multicenter, retrospective cohort study was conducted using patient data extracted from the Turkish National Electronic Database. All patients who tested positive for COVID-19 (PCR test) between 11 March through to 30 May 2020 were screened for eligibility (n = 149,671). Following exclusion of patients based on pre-determined inclusion criteria, patients with T2DM using a DPP-4i or glucose-lowering medications other than a DPP-4i were compared for mortality and hospitalization. The propensity score method was used to match age, gender, micro- and macrovascular complications, and medications in the two groups. Independent associates of mortality were analyzed using multivariable analysis on the whole T2DM population. Results A total of 33,478 patients with T2DM who tested postive for COVID-19 who met the inclusion criteria were included in the analysis. Median (interquartile range) age was 54 (22) years and 42.4% were male. Of these, 9100 patients using DPP-4is (n = 4550) or other glucose-lowering drugs (n = 4550) were matched in two groups. After matching, analysis revealed a lower mortality in the DPP-4i group (9.5 vs. 11.8%; p < 0.001). In the multivariable model, the use of DPP-4is (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.35-0.91; p = 0.02) was associated with lower mortality in the whole sample, while age, male gender, computed tomography finding of COVID-19, obesity, low glomerular filtration rate, and an insulin-based regimen also predicted increased risk of death. There was no association between the preexisting treatment with DPP-4is and COVID-19-related hospitalization in the matched analysis or multivariate model. The rate of admission to the intensive care unit and/or mechanical ventilation favored the DPP-4i group (21.7 vs. 25.2%; p = 0.001), although this association became saturated in the multivariate analysis (OR 0.65, 95% CI 0.39-1.08; p = 0.099). Conclusions The results of this study demonstrate an association between DDP-4i use and reduced mortality in people with T2DM who tested PCR positive for COVID-19.en_US
dc.identifier.doi10.1007/s13300-021-01133-8
dc.identifier.endpage2870en_US
dc.identifier.issn1869-6953
dc.identifier.issn1869-6961
dc.identifier.issue11en_US
dc.identifier.pmid34398433en_US
dc.identifier.scopus2-s2.0-85112491499en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2857en_US
dc.identifier.urihttps://doi.org/10.1007/s13300-021-01133-8
dc.identifier.urihttps://hdl.handle.net/11616/100127
dc.identifier.volume12en_US
dc.identifier.wosWOS:000685379900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofDiabetes Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectCOVID-19en_US
dc.subjectHospitalizationen_US
dc.subjectIntensive care unit admissionen_US
dc.subjectMechanical ventilationen_US
dc.subjectMortalityen_US
dc.subjectDPP-4 inhibitoren_US
dc.subjectAnti-diabetic agentsen_US
dc.titleLower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu